Virax Biolabs Group Limited
VRAX · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | -0.01 | -0.74 |
| FCF Yield | -146.36% | -502.57% | -58.96% | -0.39% |
| EV / EBITDA | 0.06 | 0.29 | 0.33 | -275,987.25 |
| Quality | ||||
| ROIC | -103.22% | -121.13% | -63.34% | 144.87% |
| Gross Margin | -838.21% | 32.34% | -15.94% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.93 | 0.77 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -9.57% | – | -58.96% | -100.00% |
| Free Cash Flow Growth | 30.28% | -70.06% | -438.66% | -37.09% |
| Safety | ||||
| Net Debt / EBITDA | 0.66 | 0.51 | 1.69 | 24.00 |
| Interest Coverage | -105.93 | -241.70 | -370.62 | -112.30 |
| Efficiency | ||||
| Inventory Turnover | 0.63 | 1.75 | 0.41 | 0.00 |
| Cash Conversion Cycle | 2,004.38 | 559.21 | -4,994.13 | 0.00 |